Eur J Pharmacol 2021 May 8;904:174143. Epub 2021 May 8.
Military Institute of Hygiene and Epidemiology, 01-163, Warsaw, Poland; Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research (CBP), Medical University of Warsaw, 02-097, Warsaw, Poland.
Disulfiram (DSF) is a well-known anti-alcohol agent that inhibits aldehyde dehydrogenase and results in extreme 'hangover' symptoms when consumed with alcohol This drug, however, has been suggested as useful in other forms of drug addiction due to its beneficial potential in both drug abuse reduction and withdrawal However, among other drugs used in alcohol dependence, it carries the greatest risk of pharmacological interactions Concomitant use of DSF and central nervous system stimulants usually leads to harmful, undesirable effects To date, there is still limited data regarding the detailed safety profile of DSF as a concomitant drug In this review article, we outline the current state of knowledge about DSF, its broad pharmacological action, as well as therapeutic effects, with a particular emphasis on the molecular understanding of its potential pharmacodynamic interactions with common addictive substances (eg, alcohol, cocaine, cannabinoids, opioids) supported by relevant examples. Read More